Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
B ChenWeimin Cai

Abstract

The purpose of the study was to elucidate the influence of multidrug resistance gene (MDR1) haplotype and CYP3A5 genotype on cyclosporine (CsA) blood level in Chinese renal transplant recipients. CsA trough level (C(0)) and peak level (C(2)) of 115 patients 1 week and 1 month after renal transplantation were determined. MDR1 C1236T, G2677T/A, C3435T and CYP3A5*3 genotypes were determined by polymerase chain reaction (PCR) assays based on amplification refractory mutation. Dose-adjusted C(0) (C(0)/D), C(2) (C(2)/D) were 50.5 +/- 22.5, 267.8 +/- 110.1 ng.kg.(ml.mg)(-1) after 1 week of therapy, and 79.3 +/- 29.4, 406.0 +/- 135.3 ng.kg.(ml.mg)(-1) after 1 month of therapy. Frequencies of MDR1 haplotype TTT, CGC, and TGC were 27.0%, 25.2% and 20.0%, respectively. After 1 month of therapy, C(2)/D of TTT/TTT patients were 30% (p = 0.057) and 53% (p = 0.003) higher than CGC/TTT and CGC/CGC patients. C(0)/D of CYP3A5 *1/*1, *1/*3 and *3/*3 patients after 1 month of therapy were 51.8 +/- 25.0, 71.5 +/- 27.6, and 86.7 +/- 28.6 ng.kg.(ml.mg)(-1) (p < 0.05). MDR1 haplotypes and CYP3A5*3 genotypes can be related to C(2) and C(0) of CsA, respectively.

References

May 28, 1992·Biochemical Pharmacology·S S ParkH V Gelboin
May 8, 1986·The New England Journal of Medicine·UNKNOWN Canadian Multicentre Transplant Study Group
Dec 1, 1995·Therapeutic Drug Monitoring·A Lindholm, J Säwe
Dec 12, 2001·Pharmacogenetics·E HustertL Wojnowski
Jul 9, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·UNKNOWN International Neoral Renal Transplantation Study Group.
Nov 7, 2002·Biological & Pharmaceutical Bulletin·Toshiyuki SakaedaKatsuhiko Okumura
Aug 2, 2003·Pharmacogenetics·Deanna L KroetzUNKNOWN Pharmacogenetics of Membrane Transporters Investigators
Oct 25, 2003·Oncogene·Suresh V AmbudkarMichael M Gottesman
Jan 30, 2004·Clinical Pharmacology and Therapeutics·Catia MarzoliniRichard B Kim
Jul 17, 2004·Transplantation·Laurence Bonhomme-FaivreVéronique Picard
Aug 7, 2004·Bioinformatics·J C BarrettM J Daly
Sep 24, 2004·Therapeutic Drug Monitoring·David I MinHoward McLeod
Oct 18, 2006·Clinical and Experimental Pharmacology & Physiology·Yong-Fang HuHong-Hao Zhou
Mar 17, 2009·Journal of Clinical Laboratory Analysis·Bing ChenWeimin Cai

❮ Previous
Next ❯

Citations

Dec 17, 2010·European Journal of Clinical Pharmacology·Bing ChenWeiMin Cai
May 29, 2013·International Journal of Pharmaceutics·Noël KnopsDirk Kuypers
Oct 7, 2011·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Satoshi UedaTsukasa Takemura
Nov 29, 2013·Biopharmaceutics & Drug Disposition·Jun LeeXiaoyang Lu
Aug 20, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ying NiHairong Qiu
Oct 12, 2012·Molecular Biology Reports·Abdullah M Al-MohizeaMohammed S Al-Dosari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.